ClinicalTrials.gg
CompletedNCT04382326Updated Dec 6, 2023Results posted

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 110 sites in 2 countries. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,997
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
2nd of 19
1,997 · median 668
Started
2020
with 4 others
Phase 3
14 of 19
1 open now
Registered
5th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 2nd largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 5th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 98 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female infants born at >36 weeks of gestation and 2 months of age at the time of consent.
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
  • Major known congenital malformation or serious chronic disorder
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results
  • Previous receipt of >1 dose of vaccine; or receipt of a single hepatitis B vaccine dose administered at >30 days old, or previous receipt of any licensed or investigational pneumococcal vaccine, or planned receipt through study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,997 participants (actual)

Study arms

  • Experimental
    20-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine

    Biological: 20-valent pneumococcal conjugate vaccine

  • Active comparator
    13-valent pneumococcal conjugate vaccine

    Pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Dose 1

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

    Time frame: Within 7 days after Dose 1

  2. Percentage of Participants With Local Reaction Within 7 Days After Dose 2

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

    Time frame: Within 7 Days After Dose 2

  3. Percentage of Participants With Local Reactions Within 7 Days After Dose 3

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

    Time frame: Within 7 days after Dose 3

  4. Percentage of Participants With Local Reactions Within 7 Days After Dose 4

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 4

  5. Percentage of Participants With Systemic Events Within 7 Days After Dose 1

    Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 1

  6. Percentage of Participants With Systemic Events Within 7 Days After Dose 2

    Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 2

  7. Percentage of Participants With Systemic Events Within 7 Days After Dose 3

    Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 3

  8. Percentage of Participants With Systemic Events Within 7 Days After Dose 4

    Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

    Time frame: Within 7 days after Dose 4

  9. Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3

    An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.

    Time frame: From Dose 1 to 1 Month after Dose 3

  10. Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.

    Time frame: From Dose 4 to 1 month after Dose 4

  11. Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months Following Dose 4

    A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalisation or prolongation of existing hospitalisation; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

    Time frame: From Dose 1 to 6 months following Dose 4

  12. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months Following Dose 4

    An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

    Time frame: From Dose 1 to 6 months following Dose 4

  13. Percentage of Participants With Predefined Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3

    Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 month after Dose 3

  14. Serotype-specific IgG Geometric Mean Concentration (GMCs) and Geometric Mean Ratios (GMRs) at 1 Month After Dose 4

    Concentrations of anticapsular IgG for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in all participants at 1 month after Dose 4 using the Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).

    Time frame: From Dose 1 to 6 months following Dose 4

  15. Percentage of Participants With Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens 1 Month After Dose 3

    Concentration of antibody to diphtheria toxoid (predefined level ≥0.1 IU/mL), tetanus toxoid (predefined level ≥0.1 IU/mL), IgG antibodies to pertussis antigens (pertussis toxin, filamentous hemagglutinin and pertactin, each with the predefined level as the 5th percentile observed in the 13vPnC group), hepatitis B antibody (in milli-international units per mL \[mIU/mL\]) (predefined level ≥10 mIU/mL), neutralizing antibody (NA) titers to poliovirus types 1, 2, and 3 (predefined level NA titer ≥1:8), Haemophilus influenzae type b (Hib) (≥0.15 μg/mL) were determined on subsets of sera collected at the immunogenicity time point 1 month after Dose 3. The antibody levels were measured by a validated multiplex Luminex immunoassay. The concomitant immune responses were measured on random subsets.

    Time frame: 1 month after Dose 3

Secondary outcomes

  1. Serotype-specific IgG GMCs and GMRs at 1 Month After Dose 3

    Pneumococcal IgG antibody against each of the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F) was measured using direct binding Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).

    Time frame: 1 month after Dose 3

  2. Percentage of Participants With Predefined IgG Concentrations 1 Month After Dose 4

    Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

    Time frame: 1 month after Dose 4

  3. Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Dose 3

    OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 3.

    Time frame: 1 month after Dose 3

  4. Serotype-specific OPA GMTs at 1 Month After Dose 4

    OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 4. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 4.

    Time frame: 1 month after Dose 4

  5. Serotype-specific IgG Geometric Mean Fold Rise (GMFRs) From 1 Month After Dose 3 to Before Dose 4

    GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 were reported from Dose 3 evaluable immunogenicity participant.

    Time frame: 1 month after Dose 3 to before Dose 4

  6. Serotype-specific IgG GMFRs From 1 Month Before to 1 Month After Dose 4

    GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month before Dose 4 to 1 month after Dose 4 were reported from Dose 4 evaluable immunogenicity participants.

    Time frame: From 1 month before to 1 month after Dose 4

  7. Serotype-specific IgG GMFRs From 1 Month After Dose 3 to 1 Month After Dose 4

    GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 were reported from participants in both Dose 3 and Dose 4 evaluable immunogenicity populations.

    Time frame: from 1 month after Dose 3 to 1 month after Dose 4

  8. Percentage of Participants With Alternative Prespecified Hib Antibody Level 1 Month After Dose 3

    Antibody concentration to the Hib vaccine antigens were determined on sera collected from a randomly selected subset of participants with sufficient sera volumes. Percentage of participants with alternative prespecified Hib antibody (≥1.0 μg/mL) were reported from Dose 3 evaluable immunogenicity participants.

    Time frame: 1 month after Dose 3

  9. Geometric Mean Ratios (GMRs) of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Measles) 1 Month After Dose 4

    Antibody concentrations to concomitant vaccine antigen (measles) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

    Time frame: 1 month after Dose 4

  10. GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Mumps) 1 Month After Dose 4

    Antibody concentrations to concomitant vaccine antigen (mumps) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

    Time frame: 1 month after Dose 4

  11. GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens (Rubella) 1 Month After Dose 4

    Antibody concentrations to concomitant vaccine antigen (rubella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

    Time frame: 1 month after Dose 4

  12. GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Varicella) 1 Month After Dose 4

    Antibody concentrations to concomitant vaccine antigen (varicella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

    Time frame: 1 month after Dose 4

07

Results

Posted Dec 6, 2023

Participant flow

Participant flow — Overall Study
Milestone20vPnC13vPnC
Started1001987
Completed821799
Not completed180188
Withdrew: Adverse event, not serious12
Withdrew: Other10
Withdrew: Withdrawal by parent/guardian5054
Withdrew: No longer meets eligibility criteria5044
Withdrew: Protocol violation2923
Withdrew: Physician decision01
Withdrew: Lost to follow-up4863
Withdrew: Adverse event, non-fatal11

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Percentage of participants20vPnC13vPnC
Redness: Any25.5 (22.8 to 28.3)24.6 (22.0 to 27.5)
Redness: Mild21.5 (18.9 to 24.1)22.3 (19.7 to 25.0)
Redness: Moderate4.0 (2.9 to 5.4)2.4 (1.5 to 3.5)
Redness: Severe0 (0.0 to 0.4)0 (0.0 to 0.4)
Swelling: Any16.4 (14.2 to 18.9)18.8 (16.4 to 21.4)
Swelling: Mild11.5 (9.6 to 13.6)14.7 (12.5 to 17.1)
Swelling: Moderate4.8 (3.6 to 6.4)4.1 (2.9 to 5.6)
Swelling: Severe0.1 (0.0 to 0.6)0 (0.0 to 0.4)
Pain at the injection site: Any49.1 (46.0 to 52.3)45.3 (42.1 to 48.5)
Pain at the injection site: Mild30.6 (27.8 to 33.6)30.4 (27.5 to 33.4)
Pain at the injection site: Moderate18.4 (16.1 to 21.0)14.9 (12.7 to 17.3)
Pain at the injection site: Severe0.1 (0.0 to 0.6)0 (0.0 to 0.4)
PrimaryPercentage of Participants With Local Reaction Within 7 Days After Dose 2

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

Time frame:
Within 7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reaction Within 7 Days After Dose 2
Percentage of participants20vPnC13vPnC
Redness: Any23.2 (20.5 to 26.0)26.4 (23.6 to 29.4)
Redness: Mild21.2 (18.6 to 23.9)23.1 (20.4 to 25.9)
Redness: Moderate2.0 (1.2 to 3.1)3.4 (2.3 to 4.7)
Redness: Severe0 (0.0 to 0.4)0 (0.0 to 0.4)
Swelling: Any15.5 (13.3 to 18.0)17.3 (14.9 to 19.9)
Swelling: Mild11.5 (9.5 to 13.7)13.5 (11.4 to 15.9)
Swelling: Moderate4.0 (2.9 to 5.5)3.8 (2.7 to 5.2)
Swelling: Severe0 (0.0 to 0.4)0 (0.0 to 0.4)
Pain at the injection site: Any44.0 (40.8 to 47.3)41.7 (38.5 to 44.9)
Pain at the injection site: Mild29.3 (26.4 to 32.3)27.7 (24.8 to 30.7)
Pain at the injection site: Moderate14.8 (12.6 to 17.2)14.0 (11.8 to 16.4)
Pain at the injection site: Severe0 (0.0 to 0.4)0 (0.0 to 0.4)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 3

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Percentage of participants20vPnC13vPnC
Redness: Any25.4 (22.6 to 28.3)27.2 (24.3 to 30.2)
Redness: Mild21.1 (18.5 to 23.9)23.5 (20.8 to 26.4)
Redness: Moderate4.3 (3.1 to 5.8)3.7 (2.5 to 5.1)
Redness: Severe0 (0.0 to 0.4)0 (0.0 to 0.4)
Swelling: Any17.1 (14.7 to 19.7)17.6 (15.2 to 20.3)
Swelling: Mild12.5 (10.4 to 14.8)13.8 (11.6 to 16.2)
Swelling: Moderate4.6 (3.3 to 6.2)3.8 (2.6 to 5.2)
Swelling: Severe0 (0.0 to 0.4)0.1 (0.0 to 0.6)
Pain at the injection site: Any38.6 (35.5 to 41.9)39.0 (35.8 to 42.2)
Pain at the injection site: Mild25.7 (22.9 to 28.7)25.5 (22.7 to 28.5)
Pain at the injection site: Moderate12.9 (10.8 to 15.3)13.4 (11.3 to 15.8)
Pain at the injection site: Severe0 (0.0 to 0.4)0 (0.0 to 0.4)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 4

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 4
Percentage of participants20vPnC13vPnC
Redness: Any23.5 (20.6 to 26.5)26.6 (23.6 to 29.8)
Redness: Mild19.6 (17.0 to 22.5)22.0 (19.2 to 25.0)
Redness: Moderate3.9 (2.7 to 5.4)4.7 (3.3 to 6.3)
Redness: Severe0 (0.0 to 0.4)0 (0.0 to 0.5)
Swelling: Any14.9 (12.5 to 17.5)17.3 (14.8 to 20.1)
Swelling: Mild10.7 (8.6 to 13.0)13.6 (11.3 to 16.2)
Swelling: Moderate4.2 (3.0 to 5.8)3.7 (2.5 to 5.2)
Swelling: Severe0 (0.0 to 0.4)0 (0.0 to 0.5)
Pain at the injection site: Any35.7 (32.4 to 39.1)35.8 (32.5 to 39.2)
Pain at the injection site: Mild24.1 (21.2 to 27.2)27.1 (24.1 to 30.3)
Pain at the injection site: Moderate11.3 (9.2 to 13.6)8.7 (6.9 to 10.9)
Pain at the injection site: Severe0.4 (0.1 to 1.1)0 (0.0 to 0.5)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1

Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature greater than or equal to (\>=) 38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Percentage of participants20vPnC13vPnC
Fever: >=38.0 degree C10.3 (8.5 to 12.3)7.5 (5.9 to 9.3)
Fever: >=38.0 degree C to 38.4 degree C7.3 (5.7 to 9.0)6.3 (4.8 to 8.0)
Fever: >38.4 degree C to 38.9 degree C2.2 (1.4 to 3.3)0.9 (0.4 to 1.7)
Fever: >38.9 degree C to 40.0 degree C0.7 (0.3 to 1.4)0.3 (0.1 to 0.9)
Fever: >40.0 degree C0.1 (0.0 to 0.6)0 (0.0 to 0.4)
Decreased appetite: Any24.4 (21.7 to 27.2)23.9 (21.3 to 26.7)
Decreased appetite: Mild14.5 (12.4 to 16.8)16.1 (13.9 to 18.6)
Decreased appetite: Moderate9.7 (7.9 to 11.7)7.5 (5.9 to 9.3)
Decreased appetite: Severe0.2 (0.0 to 0.7)0.3 (0.1 to 0.9)
Drowsiness: Any67.2 (64.2 to 70.1)66.0 (62.9 to 69.0)
Drowsiness: Mild50.2 (47.0 to 53.3)49.3 (46.1 to 52.5)
Drowsiness: Moderate16.1 (13.9 to 18.5)15.6 (13.4 to 18.0)
Drowsiness: Severe0.9 (0.4 to 1.7)1.1 (0.6 to 2.0)
Irritability: Any70.9 (68.0 to 73.7)71.7 (68.7 to 74.5)
Irritability: Mild23.4 (20.8 to 26.1)21.6 (19.0 to 24.3)
Irritability: Moderate43.0 (39.9 to 46.1)46.2 (43.0 to 49.4)
Irritability: Severe4.5 (3.3 to 6.0)3.9 (2.8 to 5.3)
Use of antipyretic or pain medication35.1 (32.2 to 38.2)33.8 (30.8 to 36.8)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2

Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Percentage of participants20vPnC13vPnC
Fever: >=38.0 degree C17.3 (15.0 to 19.9)16.3 (14.0 to 18.9)
Fever: >=38.0 degree C to 38.4 degree C10.9 (8.9 to 13.0)10.0 (8.1 to 12.1)
Fever: >38.4 degree C to 38.9 degree C4.0 (2.9 to 5.5)4.2 (3.0 to 5.7)
Fever: >38.9 degree C to 40.0 degree C2.2 (1.4 to 3.4)2.2 (1.3 to 3.3)
Fever: >40.0 degree C0.2 (0.0 to 0.8)0 (0.0 to 0.4)
Decreased appetite: Any26.4 (23.6 to 29.3)23.5 (20.8 to 26.4)
Decreased appetite: Mild16.4 (14.1 to 18.9)15.3 (13.0 to 17.7)
Decreased appetite: Moderate9.8 (8.0 to 11.9)7.7 (6.0 to 9.6)
Decreased appetite: Severe0.2 (0.0 to 0.8)0.5 (0.2 to 1.3)
Drowsiness: Any54.7 (51.4 to 57.9)55.6 (52.4 to 58.9)
Drowsiness: Mild37.0 (33.9 to 40.2)36.9 (33.8 to 40.1)
Drowsiness: Moderate16.9 (14.6 to 19.5)17.9 (15.4 to 20.5)
Drowsiness: Severe0.7 (0.3 to 1.5)0.9 (0.4 to 1.7)
Irritability: Any71.6 (68.6 to 74.5)68.8 (65.7 to 71.8)
Irritability: Mild22.9 (20.2 to 25.7)21.2 (18.6 to 24.0)
Irritability: Moderate44.7 (41.5 to 47.9)43.4 (40.2 to 46.7)
Irritability: Severe4.0 (2.9 to 5.5)4.2 (3.0 to 5.7)
Use of antipyretic or pain medication40.7 (37.6 to 44.0)41.0 (37.8 to 44.3)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 3

Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Percentage of participants20vPnC13vPnC
Fever: >=38.0 degree C12.6 (10.5 to 14.9)13.7 (11.5 to 16.1)
Fever: >=38.0 degree C to 38.4 degree C7.7 (6.0 to 9.6)7.9 (6.2 to 9.8)
Fever: >38.4 degree C to 38.9 degree C3.4 (2.3 to 4.8)3.9 (2.7 to 5.4)
Fever: >38.9 degree C to 40.0 degree C1.4 (0.8 to 2.4)1.9 (1.1 to 3.0)
Fever: >40.0 degree C0.1 (0.0 to 0.6)0 (0.0 to 0.4)
Decreased appetite: Any20.6 (18.0 to 23.3)22.4 (19.7 to 25.3)
Decreased appetite: Mild13.5 (11.3 to 15.8)13.9 (11.7 to 16.3)
Decreased appetite: Moderate6.7 (5.1 to 8.5)8.2 (6.5 to 10.2)
Decreased appetite: Severe0.4 (0.1 to 1.1)0.3 (0.1 to 1.0)
Drowsiness: Any44.1 (40.8 to 47.4)44.1 (40.8 to 47.4)
Drowsiness: Mild31.1 (28.1 to 34.2)30.1 (27.1 to 33.2)
Drowsiness: Moderate12.5 (10.4 to 14.8)13.1 (11.0 to 15.5)
Drowsiness: Severe0.5 (0.2 to 1.3)0.9 (0.4 to 1.7)
Irritability: Any64.4 (61.2 to 67.5)63.0 (59.8 to 66.2)
Irritability: Mild25.2 (22.4 to 28.1)21.6 (19.0 to 24.5)
Irritability: Moderate37.5 (34.4 to 40.8)39.2 (36.0 to 42.5)
Irritability: Severe1.8 (1.0 to 2.8)2.2 (1.4 to 3.4)
Use of antipyretic/pain medication36.3 (33.2 to 39.5)36.1 (32.9 to 39.3)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 4

Systemic events included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>= 38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.

Time frame:
Within 7 days after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 4
Percentage of participants20vPnC13vPnC
Fever: >= 38.0 degree C14.5 (12.2 to 17.1)14.0 (11.7 to 16.6)
Fever: >=38.0 degree C to 38.4 degree C6.5 (4.9 to 8.4)7.7 (6.0 to 9.8)
Fever: >38.4 degree C to 38.9 degree C5.1 (3.7 to 6.8)3.2 (2.1 to 4.6)
Fever: >38.9 degree C to 40.0 degree C2.7 (1.7 to 4.0)2.9 (1.9 to 4.4)
Fever: >40.0 degree C0.2 (0.0 to 0.9)0.1 (0.0 to 0.7)
Decreased appetite: Any24.8 (21.9 to 27.9)25.2 (22.2 to 28.3)
Decreased appetite: Mild15.9 (13.4 to 18.5)16.1 (13.6 to 18.8)
Decreased appetite: Moderate8.6 (6.8 to 10.7)8.3 (6.5 to 10.5)
Decreased appetite: Severe0.4 (0.1 to 1.1)0.7 (0.3 to 1.6)
Drowsiness: Any39.5 (36.1 to 42.9)39.5 (36.1 to 43.0)
Drowsiness: Mild27.8 (24.8 to 31.0)28.2 (25.2 to 31.4)
Drowsiness: Moderate11.0 (9.0 to 13.4)10.7 (8.6 to 13.0)
Drowsiness: Severe0.6 (0.2 to 1.4)0.6 (0.2 to 1.4)
Irritability: Any61.0 (57.6 to 64.4)61.1 (57.7 to 64.5)
Irritability: Mild23.4 (20.5 to 26.4)21.8 (19.0 to 24.8)
Irritability: Moderate35.0 (31.7 to 38.3)37.9 (34.6 to 41.3)
Irritability: Severe2.7 (1.7 to 4.0)1.3 (0.7 to 2.4)
Use of antipyretic/pain medication37.5 (34.2 to 40.9)36.7 (33.4 to 40.1)
PrimaryPercentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3

An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.

Time frame:
From Dose 1 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3
Percentage of participants20vPnC13vPnC
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 336.6 (33.6 to 39.6)39.4 (36.3 to 42.5)
PrimaryPercentage of Participants With AEs From Dose 4 to 1 Month After Dose 4

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events.

Time frame:
From Dose 4 to 1 month after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4
Percentage of participants20vPnC13vPnC
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 415.1 (12.8 to 17.7)15.0 (12.6 to 17.6)
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months Following Dose 4

A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalisation or prolongation of existing hospitalisation; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.

Time frame:
From Dose 1 to 6 months following Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months Following Dose 4
Percentage of participants20vPnC13vPnC
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 6 Months Following Dose 44.5 (3.3 to 6.0)3.1 (2.1 to 4.4)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months Following Dose 4

An NDCMC was defined as a significant disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.

Time frame:
From Dose 1 to 6 months following Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months Following Dose 4
Percentage of participants20vPnC13vPnC
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 6 Months Following Dose 45.0 (3.7 to 6.5)5.9 (4.5 to 7.5)
PrimaryPercentage of Participants With Predefined Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3

Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 month after Dose 3
Reported as:
Number · percentage of participants
Percentage of Participants With Predefined Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3
percentage of participants20vPnC13vPnC
Serotype 179.8 (76.9 to 82.5)88.4 (86.0 to 90.5)
Serotype 352.1 (48.6 to 55.5)67.6 (64.2 to 70.8)
Serotype 479.7 (76.8 to 82.4)88.2 (85.7 to 90.3)
Serotype 582.5 (79.7 to 85.0)86.8 (84.2 to 89.1)
Serotype 6A93.5 (91.6 to 95.1)95.9 (94.3 to 97.2)
Serotype 6B88.3 (85.9 to 90.4)92.4 (90.3 to 94.1)
Serotype 7F96.6 (95.2 to 97.8)97.6 (96.3 to 98.6)
Serotype 9V81.9 (79.1 to 84.4)89.8 (87.5 to 91.8)
Serotype 1493.4 (91.5 to 95.0)94.1 (92.3 to 95.7)
Serotype 18C92.6 (90.6 to 94.2)93.1 (91.2 to 94.8)
Serotype 19A97.1 (95.7 to 98.1)98.1 (96.9 to 98.9)
Serotype 19F96.9 (95.5 to 98.0)96.6 (95.1 to 97.8)
Serotype 23F77.9 (74.9 to 80.7)85.5 (82.9 to 87.9)
Serotype 896.8 (95.3 to 97.9)85.5 (82.9 to 87.9)
Serotype 10A82.2 (79.5 to 84.8)85.5 (82.9 to 87.9)
Serotype 11A92.7 (90.7 to 94.4)85.5 (82.9 to 87.9)
Serotype 12F67.5 (64.2 to 70.6)85.5 (82.9 to 87.9)
Serotype 15B98.2 (97.0 to 99.0)85.5 (82.9 to 87.9)
Serotype 22F98.3 (97.2 to 99.1)85.5 (82.9 to 87.9)
Serotype 33F86.7 (84.2 to 88.9)85.5 (82.9 to 87.9)
Statistical analysis
  • 20vPnC vs 13vPnC · Percentage difference: -8.6 · 95% CI -12.1 to -5.1
  • 20vPnC vs 13vPnC · Percentage difference: -15.5 · 95% CI -20.1 to -10.8
  • 20vPnC vs 13vPnC · Percentage difference: -8.4 · 95% CI -12.0 to -4.9
  • 20vPnC vs 13vPnC · Percentage difference: -4.3 · 95% CI -7.8 to -0.8
  • 20vPnC vs 13vPnC · Percentage difference: -2.4 · 95% CI -4.6 to -0.2
  • 20vPnC vs 13vPnC · Percentage difference: -4.1 · 95% CI -7.0 to -1.2
  • 20vPnC vs 13vPnC · Percentage difference: -1.0 · 95% CI -2.7 to 0.7
  • 20vPnC vs 13vPnC · Percentage difference: -7.9 · 95% CI -11.3 to -4.6
  • 20vPnC vs 13vPnC · Percentage difference: -0.8 · 95% CI -3.1 to 1.6
  • 20vPnC vs 13vPnC · Percentage difference: -0.6 · 95% CI -3.1 to 1.9
  • 20vPnC vs 13vPnC · Percentage difference: -1.0 · 95% CI -2.6 to 0.5
  • 20vPnC vs 13vPnC · Percentage difference: 0.2 · 95% CI -1.5 to 2.0
  • 20vPnC vs 13vPnC · Percentage difference: -7.6 · 95% CI -11.4 to -3.9
  • 20vPnC vs 13vPnC · Percentage difference: 11.2 · 95% CI 8.6 to 14.0
  • 20vPnC vs 13vPnC · Percentage difference: -3.3 · 95% CI -6.9 to 0.3
  • 20vPnC vs 13vPnC · Percentage difference: 7.1 · 95% CI 4.2 to 10.2
  • 20vPnC vs 13vPnC · Percentage difference: -18.1 · 95% CI -22.1 to -14.0
  • 20vPnC vs 13vPnC · Percentage difference: 12.7 · 95% CI 10.2 to 15.4
  • 20vPnC vs 13vPnC · Percentage difference: 12.8 · 95% CI 10.3 to 15.5
  • 20vPnC vs 13vPnC · Percentage difference: 1.1 · 95% CI -2.2 to 4.5
PrimarySerotype-specific IgG Geometric Mean Concentration (GMCs) and Geometric Mean Ratios (GMRs) at 1 Month After Dose 4

Concentrations of anticapsular IgG for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in all participants at 1 month after Dose 4 using the Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).

Time frame:
From Dose 1 to 6 months following Dose 4
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
Serotype-specific IgG Geometric Mean Concentration (GMCs) and Geometric Mean Ratios (GMRs) at 1 Month After Dose 4
microgram per milliliter (μg/mL)20vPnC13vPnC
Serotype 11.47 (1.37 to 1.57)2.12 (1.97 to 2.27)
Serotype 30.56 (0.53 to 0.60)0.85 (0.80 to 0.90)
Serotype 43.77 (3.52 to 4.04)4.84 (4.50 to 5.22)
Serotype 51.87 (1.74 to 2.00)2.51 (2.33 to 2.70)
Serotype 6A9.01 (8.45 to 9.61)11.69 (10.91 to 12.53)
Serotype 6B4.01 (3.70 to 4.35)5.74 (5.27 to 6.24)
Serotype 7F3.91 (3.70 to 4.35)5.18 (4.88 to 5.49)
Serotype 9V3.44 (3.23 to 3.67)4.30 (4.02 to 4.59)
Serotype 145.68 (5.27 to 6.12)6.34 (5.88 to 6.83)
Serotype 18C3.46 (3.24 to 3.70)4.69 (4.34 to 5.05)
Serotype 19A3.53 (3.30 to 3.77)4.13 (3.84 to 4.45)
Serotype 19F5.01 (4.68 to 5.36)5.79 (5.36 to 6.25)
Serotype 23F3.95 (3.63 to 4.31)6.18 (5.66 to 6.75)
Serotype 83.97 (3.73 to 4.22)0.03 (0.03 to 0.04)
Serotype 10A6.22 (5.75 to 6.72)0.01 (0.01 to 0.01)
Serotype 11A3.53 (3.31 to 3.78)0.02 (0.02 to 0.02)
Serotype 12F1.85 (1.73 to 1.99)0.01 (0.01 to 0.01)
Serotype 15B12.59 (11.78 to 13.45)0.02 (0.02 to 0.03)
Serotype 22F10.60 (9.92 to 11.33)0.00 (0.00 to 0.01)
Serotype 33F9.31 (8.71 to 9.96)0.01 (0.01 to 0.01)
Statistical analysis
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.69 · 95% CI 0.63 to 0.76
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.66 · 95% CI 0.61 to 0.73
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.78 · 95% CI 0.70 to 0.86
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.74 · 95% CI 0.67 to 0.82
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.77 · 95% CI 0.70 to 0.85
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.70 · 95% CI 0.62 to 0.79
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.76 · 95% CI 0.70 to 0.82
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.80 · 95% CI 0.73 to 0.88
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.90 · 95% CI 0.81 to 1.00
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.74 · 95% CI 0.67 to 0.82
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.85 · 95% CI 0.77 to 0.94
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.86 · 95% CI 0.78 to 0.96
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.64 · 95% CI 0.57 to 0.72
  • 20vPnC vs 13vPnC · Geometric mean ratio: 1.87 · 95% CI 1.71 to 2.06
  • 20vPnC vs 13vPnC · Geometric mean ratio: 2.94 · 95% CI 2.64 to 3.26
  • 20vPnC vs 13vPnC · Geometric mean ratio: 1.67 · 95% CI 1.51 to 1.84
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.88 · 95% CI 0.79 to 0.97
  • 20vPnC vs 13vPnC · Geometric mean ratio: 5.95 · 95% CI 5.39 to 6.55
  • 20vPnC vs 13vPnC · Geometric mean ratio: 5.01 · 95% CI 4.54 to 5.52
  • 20vPnC vs 13vPnC · Geometric mean ratio: 4.40 · 95% CI 3.99 to 4.85
PrimaryPercentage of Participants With Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens 1 Month After Dose 3

Concentration of antibody to diphtheria toxoid (predefined level ≥0.1 IU/mL), tetanus toxoid (predefined level ≥0.1 IU/mL), IgG antibodies to pertussis antigens (pertussis toxin, filamentous hemagglutinin and pertactin, each with the predefined level as the 5th percentile observed in the 13vPnC group), hepatitis B antibody (in milli-international units per mL \[mIU/mL\]) (predefined level ≥10 mIU/mL), neutralizing antibody (NA) titers to poliovirus types 1, 2, and 3 (predefined level NA titer ≥1:8), Haemophilus influenzae type b (Hib) (≥0.15 μg/mL) were determined on subsets of sera collected at the immunogenicity time point 1 month after Dose 3. The antibody levels were measured by a validated multiplex Luminex immunoassay. The concomitant immune responses were measured on random subsets.

Time frame:
1 month after Dose 3
Reported as:
Number · percentage of participants
Percentage of Participants With Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens 1 Month After Dose 3
percentage of participants20vPnC13vPnC
Diphtheria93.5 (90.5 to 95.8)97.8 (95.7 to 99.0)
Tetanus99.7 (98.5 to 100.0)99.4 (98.0 to 99.9)
Pertussis (PT)94.9 (92.1 to 96.9)95.0 (92.3 to 97.0)
Pertussis (FHA)95.7 (93.1 to 97.5)95.0 (92.3 to 97.0)
Pertussis (PRN)93.8 (90.8 to 96.0)95.0 (92.3 to 97.0)
hepatitis B surface antigen (HBsAg)100.0 (96.9 to 100.0)100.0 (97.1 to 100.0)
Poliovirus (Type 1)100.0 (96.7 to 100.0)100.0 (96.9 to 100.0)
Poliovirus (Type 2)100.0 (96.8 to 100.0)99.2 (95.4 to 100.0)
Poliovirus (Type 3)100.0 (96.8 to 100.0)100.0 (97.0 to 100.0)
Hib ≥0.15 μg/mL100.0 (97.1 to 100.0)100.0 (97.1 to 100.0)
Statistical analysis
  • 20vPnC vs 13vPnC · Percentage difference: -4.3 · 95% CI -7.5 to -1.4
  • 20vPnC vs 13vPnC · Percentage difference: 0.3 · 95% CI -1.0 to 1.7
  • 20vPnC vs 13vPnC · Percentage difference: -0.2 · 95% CI -3.5 to 3.1
  • 20vPnC vs 13vPnC · Percentage difference: 0.6 · 95% CI -2.5 to 3.9
  • 20vPnC vs 13vPnC · Percentage difference: -1.3 · 95% CI -4.7 to 2.2
  • 20vPnC vs 13vPnC · Percentage difference: 0.0 · 95% CI -3.2 to 2.9
  • 20vPnC vs 13vPnC · Percentage difference: 0.0 · 95% CI -3.4 to 3.2
  • 20vPnC vs 13vPnC · Percentage difference: 0.8 · 95% CI -2.4 to 4.6
  • 20vPnC vs 13vPnC · Percentage difference: 0.0 · 95% CI -3.2 to 3.1
  • 20vPnC vs 13vPnC · Percentage difference: 0.0 · 95% CI -3.0 to 3.0
SecondarySerotype-specific IgG GMCs and GMRs at 1 Month After Dose 3

Pneumococcal IgG antibody against each of the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F) was measured using direct binding Luminex assay. Results were expressed as IgG concentrations. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ.GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · μg/mL
Serotype-specific IgG GMCs and GMRs at 1 Month After Dose 3
μg/mL20vPnC13vPnC
Serotype 10.74 (0.70 to 0.79)1.14 (1.06 to 1.22)
Serotype 30.36 (0.33 to 0.38)0.51 (0.48 to 0.55)
Serotype 40.75 (0.70 to 0.81)1.08 (1.00 to 1.17)
Serotype 50.66 (0.61 to 0.71)0.96 (0.88 to 1.04)
Serotype 6A1.95 (1.81 to 2.10)2.69 (2.48 to 2.92)
Serotype 6B0.61 (0.55 to 0.68)1.02 (0.91 to 1.14)
Serotype 7F1.71 (1.62 to 1.81)2.29 (2.16 to 2.43)
Serotype 9V0.87 (0.81 to 0.93)1.21 (1.12 to 1.30)
Serotype 142.16 (2.01 to 2.33)2.72 (2.51 to 2.95)
Serotype 18C1.31 (1.23 to 1.39)1.71 (1.59 to 1.84)
Serotype 19A0.72 (0.67 to 0.76)0.91 (0.85 to 0.97)
Serotype 19F1.59 (1.50 to 1.67)2.00 (1.88 to 2.12)
Serotype 23F0.82 (0.75 to 0.90)1.25 (1.14 to 1.37)
Serotype 81.80 (1.70 to 1.91)0.02 (0.02 to 0.02)
Serotype 10A1.21 (1.09 to 1.33)0.01 (0.01 to 0.01)
Serotype 11A1.39 (1.30 to 1.48)0.02 (0.01 to 0.02)
Serotype 12F0.55 (0.50 to 0.60)0.01 (0.01 to 0.01)
Serotype 15B4.40 (4.11 to 4.71)0.03 (0.02 to 0.03)
Serotype 22F3.71 (3.45 to 3.99)0.01 (0.00 to 0.01)
Serotype 33F1.49 (1.36 to 1.64)0.02 (0.01 to 0.02)
Statistical analysis
  • 20vPnC vs 13vPnC · Geometric mean ratios: 0.65 · 95% CI 0.59 to 0.72
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.70 · 95% CI 0.64 to 0.76
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.70 · 95% CI 0.63 to 0.78
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.69 · 95% CI 0.61 to 0.77
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.72 · 95% CI 0.65 to 0.81
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.60 · 95% CI 0.51 to 0.70
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.75 · 95% CI 0.69 to 0.81
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.72 · 95% CI 0.65 to 0.80
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.79 · 95% CI 0.71 to 0.89
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.77 · 95% CI 0.70 to 0.84
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.79 · 95% CI 0.72 to 0.86
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.79 · 95% CI 0.73 to 0.86
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.66 · 95% CI 0.58 to 0.75
  • 20vPnC vs 13vPnC · Geometric mean ratio: 1.98 · 95% CI 1.81 to 2.16
  • 20vPnC vs 13vPnC · Geometric mean ratio: 1.32 · 95% CI 1.18 to 1.49
  • 20vPnC vs 13vPnC · Geometric mean ratio: 1.52 · 95% CI 1.39 to 1.67
  • 20vPnC vs 13vPnC · Geometric mean ratio: 0.60 · 95% CI 0.54 to 0.67
  • 20vPnC vs 13vPnC · Geometric mean ratio: 4.82 · 95% CI 4.39 to 5.30
  • 20vPnC vs 13vPnC · Geometric mean ratio: 4.06 · 95% CI 3.68 to 4.48
  • 20vPnC vs 13vPnC · Geometric mean ratio: 1.64 · 95% CI 1.46 to 1.83
SecondaryPercentage of Participants With Predefined IgG Concentrations 1 Month After Dose 4

Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.

Time frame:
1 month after Dose 4
Reported as:
Number · percentage of participants
Percentage of Participants With Predefined IgG Concentrations 1 Month After Dose 4
percentage of participants20vPnC13vPnC
Serotype 194.3 (92.4 to 95.8)97.2 (95.7 to 98.2)
Serotype 373.6 (70.3 to 76.8)85.8 (83.1 to 88.2)
Serotype 498.9 (97.9 to 99.5)99.1 (98.1 to 99.6)
Serotype 597.9 (96.6 to 98.8)97.7 (96.4 to 98.7)
Serotype 6A99.5 (98.6 to 99.9)99.7 (99.0 to 100.0)
Serotype 6B99.1 (98.1 to 99.6)99.5 (98.6 to 99.9)
Serotype 7F99.5 (98.6 to 99.9)99.9 (99.3 to 100.0)
Serotype 9V98.5 (97.4 to 99.3)98.9 (97.9 to 99.5)
Serotype 1498.9 (97.9 to 99.5)99.5 (98.6 to 99.9)
Serotype 18C98.9 (97.9 to 99.5)99.5 (98.6 to 99.9)
Serotype 19A99.9 (99.3 to 100.0)99.7 (99.0 to 100.0)
Serotype 19F98.8 (97.7 to 99.5)98.9 (97.9 to 99.5)
Serotype 23F97.2 (95.8 to 98.3)98.1 (96.9 to 99.0)
Serotype 899.5 (98.6 to 99.9)4.7 (3.3 to 6.5)
Serotype 10A97.7 (96.4 to 98.7)2.0 (1.1 to 3.3)
Serotype 11A98.8 (97.7 to 99.5)4.2 (2.8 to 5.9)
Serotype 12F95.2 (93.5 to 96.6)0.3 (0.0 to 1.0)
Serotype 15B99.7 (99.0 to 100.0)4.6 (3.2 to 6.3)
Serotype 22F99.6 (98.8 to 99.9)1.5 (0.7 to 2.6)
Serotype 33F99.5 (98.6 to 99.9)1.7 (0.9 to 3.0)
SecondarySerotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Dose 3

OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 3.

Time frame:
1 month after Dose 3
Reported as:
Geometric mean · Titers
Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Dose 3
Titers20vPnC13vPnC
Serotype 126 (21 to 33)34 (27 to 42)
Serotype 351 (43 to 61)63 (53 to 76)
Serotype 4339 (252 to 455)280 (207 to 378)
Serotype 532 (27 to 39)39 (32 to 47)
Serotype 6A910 (763 to 1084)936 (757 to 1156)
Serotype 6B318 (242 to 419)516 (409 to 651)
Serotype 7F1222 (1020 to 1465)1149 (926 to 1424)
Serotype 9V661 (482 to 906)594 (421 to 838)
Serotype 14415 (323 to 535)420 (330 to 535)
Serotype 18C1153 (910 to 1460)996 (754 to 1317)
Serotype 19A108 (78 to 149)109 (79 to 151)
Serotype 19F84 (67 to 105)116 (90 to 149)
Serotype 23F255 (186 to 350)295 (215 to 406)
Serotype 8665 (503 to 880)18 (17 to 20)
Serotype 10A2558 (1869 to 3501)37 (33 to 42)
Serotype 11A289 (212 to 395)50 (46 to 55)
Serotype 12F7677 (5952 to 9901)28 (24 to 33)
Serotype 15B1560 (1090 to 2233)18 (16 to 22)
Serotype 22F6797 (5170 to 8936)9 (9 to 9)
Serotype 33F7388 (4803 to 11365)198 (177 to 220)
SecondarySerotype-specific OPA GMTs at 1 Month After Dose 4

OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomized subsets of participants at 1 month after Dose 4. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution. OPA titers were determined in randomized subsets of participants at 1 month after Dose 4.

Time frame:
1 month after Dose 4
Reported as:
Geometric mean · Titers
Serotype-specific OPA GMTs at 1 Month After Dose 4
Titers20vPnC13vPnC
Serotype 136 (27 to 48)66 (50 to 87)
Serotype 362 (49 to 78)102 (86 to 120)
Serotype 4621 (435 to 887)961 (714 to 1294)
Serotype 555 (45 to 67)69 (54 to 87)
Serotype 6A1384 (1092 to 1753)1767 (1329 to 2348)
Serotype 6B666 (489 to 906)1211 (861 to 1703)
Serotype 7F2022 (1673 to 2444)2099 (1741 to 2531)
Serotype 9V2609 (1913 to 3558)3210 (2500 to 4123)
Serotype 14667 (523 to 850)593 (462 to 761)
Serotype 18C1973 (1472 to 2643)2425 (1914 to 3072)
Serotype 19A844 (622 to 1145)1357 (1007 to 1829)
Serotype 19F246 (179 to 337)373 (272 to 513)
Serotype 23F827 (554 to 1235)1532 (1118 to 2100)
Serotype 81228 (901 to 1673)26 (21 to 31)
Serotype 10A3674 (2746 to 4916)57 (44 to 74)
Serotype 11A2728 (1975 to 3768)69 (53 to 89)
Serotype 12F9320 (7037 to 12343)31 (26 to 37)
Serotype 15B3035 (2138 to 4308)23 (17 to 30)
Serotype 22F11077 (7956 to 15422)15 (11 to 20)
Serotype 33F19216 (13193 to 27990)363 (292 to 451)
SecondarySerotype-specific IgG Geometric Mean Fold Rise (GMFRs) From 1 Month After Dose 3 to Before Dose 4

GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 were reported from Dose 3 evaluable immunogenicity participant.

Time frame:
1 month after Dose 3 to before Dose 4
Reported as:
Geometric mean · Fold rise
Serotype-specific IgG Geometric Mean Fold Rise (GMFRs) From 1 Month After Dose 3 to Before Dose 4
Fold rise20vPnC13vPnC
Serotype 10.3 (0.3 to 0.3)0.3 (0.2 to 0.3)
Serotype 30.2 (0.2 to 0.2)0.2 (0.2 to 0.2)
Serotype 40.3 (0.3 to 0.4)0.3 (0.3 to 0.3)
Serotype 50.3 (0.3 to 0.3)0.3 (0.3 to 0.3)
Serotype 6A0.3 (0.3 to 0.3)0.3 (0.3 to 0.3)
Serotype 6B0.4 (0.4 to 0.4)0.3 (0.3 to 0.3)
Serotype 7F0.4 (0.4 to 0.6)0.4 (0.3 to 0.4)
Serotype 9V0.3 (0.3 to 0.4)0.3 (0.3 to 0.3)
Serotype 140.5 (0.4 to 0.5)0.5 (0.4 to 0.5)
Serotype 18C0.2 (0.2 to 0.2)0.2 (0.2 to 0.2)
Serotype 19A0.2 (0.2 to 0.2)0.2 (0.2 to 0.2)
Serotype 19F0.2 (0.2 to 0.3)0.2 (0.2 to 0.2)
Serotype 23F0.3 (0.3 to 0.3)0.3 (0.2 to 0.3)
Serotype 80.2 (0.2 to 0.3)1.4 (1.3 to 1.5)
Serotype 10A0.7 (0.6 to 0.7)0.9 (0.9 to 1.0)
Serotype 11A0.3 (0.2 to 0.3)1.1 (1.0 to 1.2)
Serotype 12F0.3 (0.3 to 0.4)1.0 (1.0 to 1.1)
Serotype 15B0.4 (0.3 to 0.4)0.8 (0.7 to 0.8)
Serotype 22F0.3 (0.3 to 0.4)0.8 (0.7 to 0.9)
Serotype 33F0.7 (0.7 to 0.8)0.8 (0.7 to 0.8)
SecondarySerotype-specific IgG GMFRs From 1 Month Before to 1 Month After Dose 4

GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month before Dose 4 to 1 month after Dose 4 were reported from Dose 4 evaluable immunogenicity participants.

Time frame:
From 1 month before to 1 month after Dose 4
Reported as:
Geometric mean · Fold rise
Serotype-specific IgG GMFRs From 1 Month Before to 1 Month After Dose 4
Fold rise20vPnC13vPnC
Serotype 17.3 (6.9 to 7.8)7.1 (6.7 to 7.6)
Serotype 38.5 (7.9 to 9.1)9.0 (8.4 to 9.6)
Serotype 415.4 (14.3 to 16.6)14.2 (13.1 to 15.3)
Serotype 6A15.2 (14.3 to 16.2)14.5 (13.1 to 15.3)
Serotype 6B18.0 (16.8 to 19.3)17.0 (15.8 to 18.2)
Serotype 7F6.0 (5.7 to 6.3)6.4 (6.0 to 6.8)
Serotype 9V11.8 (11.1 to 12.6)11.2 (10.5 to 11.9)
Serotype 145.9 (5.4 to 6.3)5.0 (4.6 to 5.3)
Serotype 58.9 (8.4 to 9.5)8.5 (8.0 to 9.0)
Serotype 18C11.3 (10.6 to 12.0)11.4 (10.7 to 12.1)
Serotype 19A25.6 (23.8 to 27.6)25.6 (23.6 to 27.7)
Serotype 19F13.1 (12.2 to 14.1)12.5 (11.6 to 13.5)
Serotype 23F18.1 (16.8 to 19.5)19.2 (17.9 to 20.6)
Serotype 89.1 (8.5 to 9.8)1.3 (1.2 to 1.4)
Serotype 10A8.1 (7.6 to 8.7)1.1 (1.0 to 1.1)
Serotype 11A9.8 (9.1 to 10.6)1.1 (1.0 to 1.2)
Serotype 12F10.0 (9.4 to 10.6)1.0 (1.0 to 1.1)
Serotype 15B8.1 (7.5 to 8.7)1.2 (1.2 to 1.3)
Serotype 22F8.4 (7.9 to 9.1)1.2 (1.1 to 1.3)
Serotype 33F8.8 (8.2 to 9.4)1.1 (1.0 to 1.1)
SecondarySerotype-specific IgG GMFRs From 1 Month After Dose 3 to 1 Month After Dose 4

GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 were reported from participants in both Dose 3 and Dose 4 evaluable immunogenicity populations.

Time frame:
from 1 month after Dose 3 to 1 month after Dose 4
Reported as:
Geometric mean · Fold rise
Serotype-specific IgG GMFRs From 1 Month After Dose 3 to 1 Month After Dose 4
Fold rise20vPnC13vPnC
Serotype 12.0 (1.9 to 2.1)1.8 (1.7 to 1.9)
Serotype 31.6 (1.5 to 1.7)1.7 (1.6 to 1.8)
Serotype 45.1 (4.8 to 5.5)4.4 (4.1 to 4.8)
Serotype 52.9 (2.7 to 3.1)2.6 (2.4 to 2.8)
Serotype 6A4.7 (4.4 to 5.0)4.3 (4.0 to 4.6)
Serotype 6B6.8 (6.2 to 7.4)5.5 (5.0 to 6.0)
Serotype 7F2.3 (2.2 to 2.4)2.2 (2.1 to 2.3)
Serotype 9V4.0 (3.7 to 4.3)3.4 (3.2 to 3.7)
Serotype 142.6 (2.4 to 2.9)2.2 (2.0 to 2.5)
Serotype 18C2.7 (2.5 to 2.8)2.6 (2.5 to 2.8)
Serotype 19A4.9 (4.6 to 5.2)4.6 (4.2 to 4.9)
Serotype 19F3.2 (3.0 to 3.4)2.9 (2.7 to 3.1)
Serotype 23F4.9 (4.5 to 5.3)4.9 (4.5 to 5.3)
Serotype 82.2 (2.0 to 2.3)1.8 (1.6 to 2.0)
Serotype 10A5.3 (4.9 to 5.8)1.0 (0.9 to 1.1)
Serotype 11A2.6 (2.4 to 2.8)1.1 (1.0 to 1.3)
Serotype 12F3.3 (3.1 to 3.6)1.0 (1.0 to 1.1)
Serotype 15B2.8 (2.6 to 3.0)1.0 (0.9 to 1.1)
Serotype 22F2.9 (2.7 to 3.1)1.0 (0.9 to 1.1)
Serotype 33F6.4 (5.9 to 7.0)0.8 (0.8 to 0.9)
SecondaryPercentage of Participants With Alternative Prespecified Hib Antibody Level 1 Month After Dose 3

Antibody concentration to the Hib vaccine antigens were determined on sera collected from a randomly selected subset of participants with sufficient sera volumes. Percentage of participants with alternative prespecified Hib antibody (≥1.0 μg/mL) were reported from Dose 3 evaluable immunogenicity participants.

Time frame:
1 month after Dose 3
Reported as:
Number · percentage of participants
Percentage of Participants With Alternative Prespecified Hib Antibody Level 1 Month After Dose 3
percentage of participants20vPnC13vPnC
Percentage of Participants With Alternative Prespecified Hib Antibody Level 1 Month After Dose 375.0 (66.4 to 82.3)72.0 (63.3 to 79.7)
SecondaryGeometric Mean Ratios (GMRs) of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Measles) 1 Month After Dose 4

Antibody concentrations to concomitant vaccine antigen (measles) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

Time frame:
1 month after Dose 4
Reported as:
Geometric mean · AU/mL
Geometric Mean Ratios (GMRs) of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Measles) 1 Month After Dose 4
AU/mL20vPnC13vPnC
Geometric Mean Ratios (GMRs) of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Measles) 1 Month After Dose 4277.74 (243.88 to 316.30)215.41 (184.61 to 251.35)
Statistical analysis
  • 20vPnC vs 13vPnC · Geometric mean ratios: 1.29 · 95% CI 1.05 to 1.58
SecondaryGMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Mumps) 1 Month After Dose 4

Antibody concentrations to concomitant vaccine antigen (mumps) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

Time frame:
1 month after Dose 4
Reported as:
Geometric mean · AU/mL
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Mumps) 1 Month After Dose 4
AU/mL20vPnC13vPnC
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Mumps) 1 Month After Dose 436.96 (30.82 to 44.33)34.19 (28.94 to 40.39)
Statistical analysis
  • 20vPnC vs 13vPnC · Geometric mean ratios: 1.08 · 95% CI 0.85 to 1.38
SecondaryGMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens (Rubella) 1 Month After Dose 4

Antibody concentrations to concomitant vaccine antigen (rubella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

Time frame:
1 month after Dose 4
Reported as:
Geometric mean · IU/mL
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens (Rubella) 1 Month After Dose 4
IU/mL20vPnC13vPnC
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigens (Rubella) 1 Month After Dose 449.63 (43.88 to 56.13)40.44 (35.19 to 46.48)
Statistical analysis
  • 20vPnC vs 13vPnC · Geometric mean ratios: 1.23 · 95% CI 1.02 to 1.48
SecondaryGMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Varicella) 1 Month After Dose 4

Antibody concentrations to concomitant vaccine antigen (varicella) were determined on sera collected 1 month after Dose 4 from a randomly selected subset of participants with sufficient sera volumes. GMs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs based on the Student's t distribution and were reported from Dose 4 evaluable immunogenicity participants.

Time frame:
1 month after Dose 4
Reported as:
Geometric mean · mIU/mL
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Varicella) 1 Month After Dose 4
mIU/mL20vPnC13vPnC
GMRs of Prespecified Antibody Levels to Specific Concomitant Vaccine Antigen (Varicella) 1 Month After Dose 4233.05 (207.25 to 262.06)234.78 (208.84 to 263.94)
Statistical analysis
  • 20vPnC vs 13vPnC · Geometric mean ratios: 0.99 · 95% CI 0.84 to 1.17

Adverse events

Collected over Local reactions (LR) and systemic events (SE) [systematic assessment(SA)]:within 7 days after Dose 1, 2, 3, 4; SAEs: from Dose 1 up to 6 months after Dose 4; other AEs [non-systematic assessment (non-SA)]:from Dose 1 up to 1 month after Dose 3 and from Dose 4 up to 1 month after Dose 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20vPnC0/1,001 (0%)45/1,001 (4.5%)966/1,001 (96.5%)
13vPnC0/987 (0%)31/987 (3.1%)939/987 (95.1%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
Event20vPnC13vPnC
Respiratory syncytial virus bronchiolitisInfections and infestations7/10013/987
GastroenteritisInfections and infestations0/10015/987
Respiratory syncytial virus infectionInfections and infestations5/10012/987
BronchiolitisInfections and infestations4/10014/987
Escherichia urinary tract infectionInfections and infestations0/10012/987
Febrile convulsionNervous system disorders2/10012/987
PneumoniaInfections and infestations2/10011/987
DehydrationMetabolism and nutrition disorders2/10011/987
Failure to thriveMetabolism and nutrition disorders2/10011/987
Microcytic anaemiaBlood and lymphatic system disorders0/10011/987
Most frequent other events
Most frequent other events
Event20vPnC13vPnC
Irritability (IRRITABILITY)Psychiatric disorders894/1001863/987
Hypersomnia (INCREASED SLEEP)Nervous system disorders823/1001798/987
Injection site pain (PAIN)General disorders689/1001663/987
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders521/1001492/987
Injection site erythema (REDNESS)General disorders498/1001492/987
Injection site swelling (SWELLING)General disorders353/1001359/987
Pyrexia (FEVER)General disorders322/1001314/987
Upper respiratory tract infectionInfections and infestations114/1001112/987
Otitis mediaInfections and infestations56/100150/987

Baseline characteristics

Safety population included all participants who received at least 1 dose of 20vPnC or 13vPnC and had safety data assessed after any dose.

Age, Continuous
Age, Continuous(Days)20vPnC13vPnCTotal
Mean65.9 ± 7.9865.6 ± 7.1265.8 ± 7.56
Sex: Female, Male
Sex: Female, Male(Participants)20vPnC13vPnCTotal
Female483482965
Male5185051023
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20vPnC13vPnCTotal
Hispanic or Latino312293605
Not Hispanic or Latino6616591320
Unknown or Not Reported283563
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20vPnC13vPnCTotal
American Indian or Alaska Native437
Asian161632
Native Hawaiian or Other Pacific Islander224
Black or African American110108218
White7547421496
More than one race6873141
Unknown or Not Reported474390
08

Study locations

110 sites
  • Children's of Alabama
    Birmingham, Alabama 35233, United States
  • UAB Pediatric Primary Care Clinic at Children's of Alabama
    Birmingham, Alabama 35233, United States
  • Southeastern Pediatric Associates
    Dothan, Alabama 36305, United States
  • MedPharmics, LLC
    Phoenix, Arizona 85015, United States
  • Northwest Arkansas Pediatrics
    Fayetteville, Arkansas 72703, United States
  • The Children's Clinic of Jonesboro, P.A.
    Jonesboro, Arkansas 72401, United States
  • Gardens Medical Center
    Bell Gardens, California 90201, United States
  • Coast Clinical Research, LLC
    Bellflower, California 90706, United States
  • Priti Desai, M.D. Inc.
    Covina, California 91723, United States
  • Universal Biopharma Research Institute Inc.
    Fresno, California 93703, United States
  • Matrix Clinical Research
    Gardena, California 90247, United States
  • Advanced Investigative Medicine, Inc.
    Hawthorne, California 90250, United States
  • Kaiser Permanente Oakland
    Oakland, California 94611, United States
  • Orange County Research Institute
    Ontario, California 91762, United States
  • Center for Clinical Trials of San Gabriel
    West Covina, California 91790, United States
  • Children's Colorado Health Pavilion (Child Health Clinic)
    Aurora, Colorado 80011, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Optumcare Colorado Springs, LLC
    Colorado Springs, Colorado 80906, United States
  • Optumcare Colorado Springs, LLC
    Colorado Springs, Colorado 80922, United States
  • Gentle Medicine Associates
    Boynton Beach, Florida 33435, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Benton Pediatrics
    Gainesville, Florida 32653, United States
  • Qway Research
    Hialeah, Florida 33010, United States
  • Next Phase Research Alliance
    Homestead, Florida 33030, United States
  • Axcess Medical Research
    Loxahatchee Groves, Florida 33470, United States
  • Crystal Biomedical Research, LLC
    Miami Lakes, Florida 33014, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Suncoast Research Associates, LLC
    Miami, Florida 33173, United States
  • Bio-Medical Research, LLC
    Miami, Florida 33184, United States
  • Children's Health Center
    Tampa, Florida 33617, United States
  • Tekton Research, Inc
    Chamblee, Georgia 30341, United States
  • Uptown Pediatrics
    Columbus, Georgia 31901, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Meridian Clinical Research
    Macon, Georgia 31210, United States
  • Omega Pediatrics
    Roswell, Georgia 30076, United States
  • Idaho Falls Pediatrics
    Ammon, Idaho 83406, United States
  • Idaho Falls Pediatrics
    Idaho Falls, Idaho 83402, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Family First Medical Center
    Idaho Falls, Idaho 83404, United States
  • Snake River Research, PLLC
    Idaho Falls, Idaho 83404, United States
  • The Pediatric Center
    Idaho Falls, Idaho 83404, United States
  • Saltzer Health
    Nampa, Idaho 83686, United States
  • ASR, LLC
    Nampa, Idaho 83687, United States
  • The Iowa Clinic
    Ankeny, Iowa 50023, United States
  • Blank Children's Pediatric Clinic
    Des Moines, Iowa 50309, United States
  • Unity Point Health
    Des Moines, Iowa 50309, United States
  • The Iowa Clinic
    West Des Moines, Iowa 50266, United States
  • Alliance for Multispecialty Research, LLC
    El Dorado, Kansas 67042, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Michael W. Simon, MD, PSC
    Lexington, Kentucky 40517, United States
  • Novak Center for Children's Health
    Louisville, Kentucky 40202, United States
  • Brownsboro Park Pediatrics
    Louisville, Kentucky 40207, United States
  • Velocity Clinical Research at Primary Pediatrics, Macon
    Baton Rouge, Louisiana 70809, United States
  • Benchmark Research
    Covington, Louisiana 70433, United States
  • ACC Pediatric Research
    Haughton, Louisiana 71037, United States
  • Velocity Clinical Research, Covington
    Metairie, Louisiana 70006, United States
  • University of Maryland, Baltimore, Center for Vaccine Development and Global Health
    Baltimore, Maryland 21201, United States
  • The Pediatric Center of Frederick, LLC
    Frederick, Maryland 21702, United States
  • MedPharmics, LLC
    Gulfport, Mississippi 39503, United States
  • Boeson Research
    Missoula, Montana 59804, United States
  • Meridian Clinical Research
    Hastings, Nebraska 68901, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68504, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68516, United States
  • Children's Physicians Dundee
    Omaha, Nebraska 68132, United States
  • Medpharmics
    Albuquerque, New Mexico 87102, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Child Health Care Associates
    East Syracuse, New York 13057, United States
  • Smart Medical Research, Inc
    Jackson Heights, New York 11372, United States
  • Child Health Care Associates
    Liverpool, New York 13090, United States
  • ECU Physicians Adult and Pediatric Health Center
    Greenville, North Carolina 27834, United States
  • ECU Physicians Pediatric Outpatient Clinic
    Greenville, North Carolina 27834, United States
  • Leo Jenkins Cancer Center Pharmacy
    Greenville, North Carolina 27834, United States
  • Dayton Clinical Research
    Dayton, Ohio 45409, United States
  • Ohio Pediatric Research Association, Inc.
    Dayton, Ohio 45414, United States
  • Pediatric Associates of Fairfield
    Fairfield, Ohio 45014, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Pediatric Medical Associates
    East Norriton, Pennsylvania 19401, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • Lockman & Lubell Pediatric Associates
    Fort Washington, Pennsylvania 19034, United States
  • Coastal Pediatric Research
    Charleston, South Carolina 29414, United States
  • Palmetto Pediatrics, PA
    North Charleston, South Carolina 29406-9170, United States
  • Sanford Children's Specialty Clinic
    Sioux Falls, South Dakota 57105, United States
  • Sanford 69th & Louise Family Medicine
    Sioux Falls, South Dakota 57108, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Premier Medical Group
    Clarksville, Tennessee 37040, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • LeBonheur Children's Hospital
    Memphis, Tennessee 38104, United States
  • Coastal Bend Clinical Research
    Corpus Christi, Texas 78413, United States
  • Kool Kids Pediatrics
    Houston, Texas 77065, United States
  • La Providence Pediatrics Clinic
    Houston, Texas 77071, United States
  • Houston Clinical Research Associates
    Houston, Texas 77090, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Diagnostic Clinic of Longview
    Longview, Texas 75605, United States
  • Ashley Pediatrics Day and Night Clinic
    McAllen, Texas 78503, United States
  • Dr. Ruben Aleman & Associates
    McAllen, Texas 78504, United States
  • Tekton Research, Inc
    San Antonio, Texas 78244, United States
  • Wee Care Pediatrics
    Kaysville, Utah 84037, United States
  • Wee Care Pediatrics
    Layton, Utah 84041, United States
  • Wasatch Pediatrics, Cottonwood Office
    Murray, Utah 84107, United States
  • Wee Care Pediatrics
    Roy, Utah 84067, United States

Showing the first 100 of 110 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Sep 2022, 27 months.

Results were first posted in Dec 2023, 1 year 3 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 27 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 11, 2020
StartActual
May 20, 2020
Primary completionActual
Sep 2, 2022
CompletionActual
Sep 2, 2022
Results first posted
Dec 6, 2023
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04382326
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 11, 2020
Start date
May 20, 2020
Primary completion
Sep 2, 2022
Completion
Sep 2, 2022
Results posted
Dec 6, 2023
Last update
Dec 6, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion